PDCD1 and lip and oral cavity carcinoma: One death (0.7%) was reported in the monotherapy group, while there were no deaths in the combination group.<h4>Conclusion</h4>In the adjuvant treatment of high-risk postoperative oral cancer patients, sequential PD-1 inhibitor can significantly improve patient survival benefits, but the incidence of adverse events is higher.